A phase II trial of ramucirumab and docetaxel as second-line treatment for patients with advanced gastric cancer (HGCSG 1903)
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Ramucirumab has shown efficacy in combination with paclitaxel in the second-line treatment of advanced gastric cancer (AGC). The efficacy and safety regarding the combination therapy of ramucirumab and docetaxel have not been reported. This treatment could reduce the incidence of neuropathy and patients' hospital visits. METHODS: on day1 of a 28-day cycle. The primary endpoint was overall response rate (ORR). The secondary endpoints were progression-free survival (PFS), overall survival (OS), relative dose intensity, and safety. RESULTS: A final analysis of efficacy and safety was performed in 35 patients. ORR was 25.7% (90% confidence interval [CI] 14.1-40.6) and disease control rate was 74.3% (90%CI 59.4-85.9). Median PFS and OS were 3.1 months (95%CI 2.1-4.2) and 11.5 months (95%CI 9.2-13.9), respectively. Grade 3 or higher adverse events that occurred in more than 10% of patients were neutropenia, leucopenia, febrile neutropenia, hypertension, and anorexia. The study protocol was amended to allow primary granulocyte-colony stimulating factor (G-CSF) prophylaxis during study period. There was no one incident febrile neutropenia after the protocol amendment. Peripheral sensory neuropathy occurred in 65.7% of all grades, with no incidence of grade 3 or higher. CONCLUSIONS: The combination therapy of ramucirumab and docetaxel demonstrated some efficacy for AGC. Caution is required regarding the occurrence of febrile neutropenia. This treatment might be considered as an option for second-line treatment of patients with AGC.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- A phase II trial of ramucirumab and docetaxel as second-line treatment for patients with advanced gastric cancer (HGCSG 1903)
- Date Crossref
- 04/05/2026
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Hokkaido University Hospital Division of Cancer Center pays non établi dans la noticeÉtablissement de santé
-
Kushiro Rosai Hospital Department of Medical Oncology pays non établi dans la noticeÉtablissement de santé
-
University of Toyama Third Department of Internal Medicine pays non établi dans la noticeUniversité ou école supérieure
-
NTT Medical Center pays non établi dans la noticeÉtablissement de santé
-
KKR Sapporo Medical Center Department of Medical Oncology pays non établi dans la noticeÉtablissement de santé
-
Sapporo City General Hospital Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Hakodate National Hospital pays non établi dans la noticeÉtablissement de santé
-
Hakodate Municipal Hospital Department of Gastroenterology pays non établi dans la noticeÉtablissement de santé
-
Teine Keijinkai Hospital Department of Medical Oncology pays non établi dans la noticeÉtablissement de santé
-
Hirosaki University Department of Medical Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Miwa Hospital pays non établi dans la noticeÉtablissement de santé
-
Nakadōri General Hospital Department of Gastroenterological Surgery pays non établi dans la noticeÉtablissement de santé
Division of Cancer Center — Hokkaido University Hospital, Department of Medical Oncology — Kushiro Rosai Hospital et Third Department of Internal Medicine — University of Toyama, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.